en · de · es · fr · pt
selank-notes.peptides9000.com › Info › Peptide Identity And Structure — Explained

Peptide Identity And Structure — Explained

By Editorial Desk · published 2026-02-07 · last reviewed 2026-03-24 · Info

The short version of proteolysis fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-03-24. Anything still debated is marked as such rather than presented as settled.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

Selank Origin and Chemical Identity

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank at a glance

PropertyValueNotes
Peptide sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSeven residues; tuftsin plus a Pro-Gly-Pro tail
Molecular formulaC33H57N11O9Commonly reported value for the free peptide
Monoisotopic massRoughly 751.4 DaAverage molecular mass near 751.9 Da
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classFreely soluble in waterAlso dissolves in saline and other polar solvents

Selank Handling, Stability, and Analysis

Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.

Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.

Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.

Related pages on this site

Background and Molecular Identity

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Stability, Handling, and Analytical Control

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Reference notes

Quisqualic acid is an agonist of the AMPA, kainate, and group I metabotropic glutamate receptors. It is one of the most potent AMPA receptor agonists known. It causes excitotoxicity and is used in neuroscience to selectively destroy neurons in the brain or spinal cord. Quisqualic acid occurs naturally in the seeds of Quisqualis species. Research conducted by the USDA Agricultural Research Service, has demonstrated quisqualic acid is also present within the flower petals of zonal geranium (Pelargonium x hortorum) and is responsible for causing rigid paralysis of the Japanese beetle. Quisqualic acid is thought to mimic L-glutamic acid, which is a neurotransmitter in the insect neuromuscular junction and mammalian central nervous system.

=== Brain damage === Despite the balance of palliative benefits which planned courses of therapy can confer when patients face serious medical conditions, long-term ketamine abuse is known to cause brain damage, including reduction in both white and grey matter seen on MRI imaging and atrophy seen on CT scans. Cognitive deficits as well as increased dissociation and delusions were observed in frequent recreational users of ketamine.

== Debate over insects' capacity for welfare == Scientists remain uncertain about the existence and degree of pain in invertebrates, including insects. However, a recent review of the neurobiological and behavioral evidence consistent with the hypothesis of pain found strong evidence consistent with precautionary treatment in at least two orders of insects at the adult life stage (Blattodea and Diptera), ultimately considering evidence from over 350 studies. This may explain why 67% of surveyed animal behavior researchers ascribed emotions (of which pain is one), to some, most, nearly all or all insects and why 82% of surveyed entomologists stated they cared about insect welfare due to the intrinsic value of the animal. Both the 2012 Cambridge Declaration on Consciousness, and the 2024 New York Declaration on Animal Consciousness, suggest that there is a realistic possibility of insect consciousness; the New York Declaration signed by many animal ethicists, welfare scientists, neuroscientists, entomologists, and consciousness researchers. As a result of the growing evidence base supporting the plausibility of insect pain and sentience, insect welfare is being increasingly discussed in all settings where insects are used and managed, including laboratory settings. Vincent Wigglesworth suggested a precautionary approach of anaesthetizing insects during potentially painful procedures. John Cooper has written about techniques for "Anesthesia, analgesia, and euthanasia of invertebrates" including insects. Neil A. C.

Sources: en.wikipedia.org

Notes from published material

=== Absorption and drug action === Particle size and surface area influence the drug absorption and subsequently the therapeutic action. The higher the dissolution, the faster the absorption and hence the quicker and greater the drug action.

For magnetic resonance angiography (MRA), ToF is a major underlying method. In this method, blood entering the imaged area is not yet saturated, giving it a much higher signal when using short echo time and flow compensation. It can be used in the detection of aneurysm, stenosis or dissection. In time-of-flight mass spectrometry, ions are accelerated by an electrical field to the same kinetic energy with the velocity of the ion depending on the mass-to-charge ratio. Thus the time-of-flight is used to measure velocity, from which the mass-to-charge ratio can be determined. The time-of-flight of electrons is used to measure their kinetic energy. In near-infrared spectroscopy, the ToF method is used to measure the media-dependent optical pathlength over a range of optical wavelengths, from which composition and properties of the media can be analyzed. In ultrasonic flow meter measurement, ToF is used to measure speed of signal propagation upstream and downstream of flow of a media, in order to estimate total flow velocity. This measurement is made in a collinear direction with the flow. In planar Doppler velocimetry (optical flow meter measurement), ToF measurements are made perpendicular to the flow by timing when individual particles cross two or more locations along the flow (collinear measurements would require generally high flow velocities and extremely narrow-band optical filters).

Oral fluphenazine rapidly absorbs and plasma levels peak at about 1.0-2.5 ng/mL 2 hours post-ingestion. The volume of distribution is about 298 L due to extensive tissue uptake, and it crosses the blood brain barrier. Bioavailability is low at 2.7% due to first pass metabolism, and the half-life is about 14–16 hours. Steady state concentrations vary considerably across individuals, which indicates variability in absorption, metabolism, or excretion. Additionally, the dose-level relationship is curvilinear with plasma levels of 0.2 - 2.8 ng/mL being optimal for clinical improvement. Fluphenazine is primarily metabolized to fluphenazine sulfoxide by the cytochrome P450 2D6. Benztropine mesylate did not indicate any major drug-drug interactions. Fluphenazine is exreted primarily through urine and feces. Injectable fluphenazine is dissolved in sesame oil which forms a localized oil depot in the muscle. Due to the lipophilicity of the added decanoate or enanthate group, the drug remains in the oil causing the rate-limiting step for drug being diffusion out, resulting in flip-flop kinetics. Fluphenazine decanoate and enanthate are prodrugs which are hydrolyzed by esterases to fluphenazine. The fluphenazine decanoate acts within 1–3 days, and its effect lasts an average of 2 weeks. The half-life of fluphenazine decanoate is about 6.8-9.6 days, and plasma levels peak at about 2.18 ng/mL about 4–6 hours post injection. Fluphenazine enanthate has a lower half life of about 3.6-3.7 days, reflecting its decreased lipophilicity.

Sources: en.wikipedia.org

Frequently asked questions

What is the primary sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.

Is Selank found naturally in the body?

No peptide with this exact sequence has been identified as an endogenous substance. It is a laboratory-designed analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro extension has no known natural source.

Why does the peptide contain three proline residues?

Proline introduces conformational constraints that make a peptide less accessible to common peptidases. This is a standard stabilization strategy in peptide design. The added residues also increase the distance between the active tuftsin portion and typical cleavage sites.

What is Selank?

Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.

Network